Stock News

Ascendis Pharma Stock Climbing: What’s Next?

Jack KelloggAvatar
Written by Jack Kellogg
Updated 3/17/2025, 5:03 pm ET 5 min read

Positive news on Ascendis Pharma A/S, including breakthrough clinical trial results for a new therapy, has triggered a rally, with shares trading up by 10.79 percent on Monday.

Latest Developments and Insights

  • Specialised Therapeutics has announced the approval of YORVIPATH by TGA for treating chronic hypoparathyroidism, making it the first medicine listed for this condition in Australia.
  • Morgan Stanley increased its price target on Ascendis Pharma to $180 from $175, maintaining an Equal Weight rating after evaluating Q4 results.
  • Ascendis Pharma’s ADRs increased by 4.9%, showcasing significant interest and positive sentiment among investors in the European pharmaceutical market.

Candlestick Chart

Live Update At 17:02:52 EST: On Monday, March 17, 2025 Ascendis Pharma A/S stock [NASDAQ: ASND] is trending up by 10.79%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Recent Earnings and Financial Overview

Many traders often rush into trading without waiting for the right opportunity, which can lead to significant losses. As millionaire penny stock trader and teacher Tim Sykes says, “Be patient, don’t force trades, and let the perfect setups come to you.” Following this advice, traders should focus on learning to identify ideal market conditions and entry points. By doing so, they increase their chances of success and minimize unnecessary risks. Patience, discipline, and the ability to read market trends are essential skills that can greatly improve one’s trading performance.

Ascendis Pharma A/S has been stirring interest with its latest innovations and moves in the pharmaceutical sector. Their revenue stands at approximately $266.7M, though key ratios reveal there’s more beneath the surface. With total assets around $825.6M against liabilities of $971.3M, one can’t ignore the tension between growth potential and financial constraints. The gross margin remains unspecified, but interestingly, the pretax profit margin is shockingly low at around -1,751.5%, raising questions about their cost management and profitability.

The company has a compelling story through its application of TransCon technology, aiming to address unmet medical needs. However, their P/S ratio of 23.39 suggests a premium valuation, making investors ponder if the price truly reflects potential future earnings. Despite challenges, Ascendis proudly maintains $392.2M in cash and equivalents, emphasizing its robust liquidity position.

More Breaking News

From its closing price on Feb 27, 2025, of $154.58, steady ascension followed, culminating on Mar 17, where the stock settled at $168.84. This upward trajectory is backed not just by strategic product approvals but significant backing from financial institutions like Morgan Stanley that foresees optimistic outcomes.

Driving Factors Behind Stock Price Movement

Over the weeks, Ascendis Pharma’s notable achievements have contributed significantly to its rising stock value. The approved YORVIPATH therapy creates a new revenue stream and strengthens its brand in chronic hypoparathyroidism solutions. Such approvals serve as catalysts by underpinning heightened market confidence and signify the company’s scientific prowess and market adaptability.

Morgan Stanley’s revised stance, aligning with Ascendis Pharma’s promising pipeline, is another layer adding sheen to its market lustre. The raised price target and maintained Equal Weight rating come as affirmations of the company’s strides forward despite financial hurdles. Combined with stock price trends showing steady growth, one might consider these dynamics as solid evidence for potential bullish sentiment in the short to mid-term.

Furthermore, their participation in significant events like the TD Cowen Health Care Conference, where insights into their innovative TransCon technology were shared, reinforces their position in the healthcare field and potentially attracts more stakeholders eager to leverage such foresight.

Conclusion: Assessing the Path Forward for ASND

The narrative around Ascendis Pharma remains one of a complex balance between innovation, financial challenges, and market performance. While there are bumps along the way, including their substantial liabilities and a stark pretax profit margin, their consistent progress in treatments and breakthroughs present a promising outlook.

Traders keen on biotech advancements should keep an eye on developments such as YORVIPATH’s commercial performance and further endorsements from financial analysts. As millionaire penny stock trader and teacher Tim Sykes, says, “Cut losses quickly, let profits ride, and don’t overtrade.” This advice seems particularly relevant as Ascendis Pharma’s momentum is an exciting story about overcoming adversities, charting new horizons, and redefining potential within pharmaceutical ventures. Is this growth sustainable? Only time will unfurl the answer, but the journey certainly offers an engaging spectacle.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:


How much has this post helped you?



Leave a reply

Author card Timothy Sykes picture

Jack Kellogg

He teaches webinars on Tim Sykes’ Trading Challenge He became Tim’s youngest millionaire student in 2020. Now he’s second on the Trading Challenge leaderboard with $12.9 million in career earnings. He’s a master of the 7-Step Pennystocking Framework. Jack is one of a rare breed of traders to profitably trade the entire penny stock framework.
Read More

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”

ts swipe photo
Stay Ahead Of The News - Sign Up For My Weekly Newsletter
Get My Watchlist Here